Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
An HIV clinic saw a 31% lower likelihood of viral suppression after transitioning to telehealth due to COVID-19.
A new CDC model shows the potential power of Undetectable = Untransmittable to curb HIV rates by 2027.
The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.
Kenya has been using similar technology for three years. DC’s efforts are among the first in the United States.
The HIV regimen failed only a few study participants.
Findings confirm that Trogarzo maintains viral load suppression for nearly 10 years.
Larger studies suggest people living with HIV might have a modestly higher risk of severe COVID-19, but much remains to be learned.
SARS-CoV-2 may have subtle effects on immunological and virological outcomes among people with HIV.
Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
Young long-term survivors continue to face challenges.
A mid-stage trial shows islatravir plus Pifeltro shows promise as two-drug HIV regimen.
The Department of Defense model of HIV care appears very successful, according to a recent study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.